Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-3R is a research peptide sold for laboratory use only — it is not intended for human consumption. These statements have not been evaluated by the FDA. Always consult your healthcare provider.
Peptide Sciences' Retatrutide: Most-Tested Vendor, Most Inconsistent Results
Peptide Sciences has become the largest supplier of research-grade retatrutide by testing volume, with 41 independent quality assays on record between June 2025 and July 2026. Yet this distinction masks a troubling reality: only 51% of those tests passed. The vendor's Finnrick Analytics rating for GLP-3R stands at 56%—a score that ranks it #1 by volume alone, not by quality. For a compound generating significant interest in the research community due to its triple-receptor agonist mechanism and potential superiority over semaglutide and tirzepatide, this inconsistency raises serious questions about what customers are actually receiving when they purchase from Peptide Sciences.
The Identity Crisis: Zero Milligram Detections and Missing Retatrutide
The most alarming finding in Peptide Sciences' retatrutide testing record involves repeated identity failures, where assays detected 0 mg of retatrutide in samples that should have contained measurable quantities. These are not marginal shortfalls or minor potency variations—they represent vials that may have contained no active retatrutide whatsoever. Identity failures of this magnitude suggest either serious manufacturing errors, cross-contamination, mislabeling, or supply chain breakdowns at the production or fulfillment stage. When a research peptide fails to contain the advertised compound in detectable amounts, the entire premise of the purchase collapses. Researchers ordering retatrutide for in vitro or animal model studies cannot rely on dose-response relationships, mechanism validation, or reproducible results if the compound itself is absent. Tutela Medical's review of the data indicates that identity failures clustered across multiple batches and time periods, suggesting a systemic rather than isolated issue.
Overfilling, Purity Inconsistency, and Manufacturing Control
Beyond identity problems, Peptide Sciences' retatrutide batches have exhibited significant overfilling—some samples containing +45% to +46% more solution than labeled. While overfilling might seem beneficial at first glance, it indicates poor quality control and raises questions about the accuracy of concentration reporting. If a vial labeled as containing 10 mg actually holds 14.6 mg due to overfilling, the stated concentration is meaningless, and researchers relying on precise dosing cannot trust the label. Purity results, when retatrutide was actually present, clustered around 99.0% to 99.4%—technically adequate but consistently falling short of industry standards of 99.5% or higher. The combination of identity failures, overfilling, and marginal purity suggests that Peptide Sciences' manufacturing or quality control processes for retatrutide may lack the rigor needed for research-grade compounds.
Erratic Batch Quality and Post-Shutdown Testing Patterns
Public testing data from spring 2026 onward reveals erratic swings in batch quality. Some periods showed consecutive failures; later samples recovered acceptable results. This volatility suggests ongoing instability in production or sourcing, not a one-time correction. Additionally, many samples lacked proper batch identification and traceability information, making it difficult to correlate test results with specific manufacturing dates or lot numbers. Researchers unable to trace their samples to documented test records have no means of verifying what they received or comparing their results to known quality benchmarks. This traceability gap undermines the scientific rigor that research-grade peptides are supposed to support.
The Paradox: High Volume, Low Quality—And Mixed Results on Other Products
Tutela Medical notes a significant paradox in Peptide Sciences' overall vendor profile. While the company ranks #1 by testing volume for retatrutide, its general Finnrick Analytics rating across all products is only 61%, placing it at #241 of 274 vendors overall. More intriguingly, Peptide Sciences performs substantially better on other peptides: semaglutide scores 81%, GHK-Cu achieves 92%, and PT-141 reaches 79%. Conversely, other products show poor results—CJC-1295 at 16% and Tesamorelin at 40%. This mixed performance suggests that retatrutide quality issues may be product-specific rather than reflecting the vendor's baseline capabilities across the board. The question becomes: why does Peptide Sciences struggle so visibly with retatrutide while performing acceptably on other compounds? The answer could involve supplier sourcing, manufacturing partnership differences, or insufficient process validation for a newer, more complex triple-agonist molecule.
Retatrutide in Research Context: Why Consistency Matters
Retatrutide represents a significant advancement in receptor agonism research. As a triple-agonist targeting GLP-1R, GIPR, and GCGR—compared to semaglutide's single receptor or tirzepatide's dual action—the compound has demonstrated approximately 28% to 30% body weight reduction in Eli Lilly's Phase 3 TRIUMPH trials. FDA approval of the pharmaceutical form is anticipated around 2027. For academic and institutional research teams studying GLP-1/GIP/glucagon signaling, GLP-3R represents a valuable research tool. However, that value evaporates if batches contain no retatrutide, are mislabeled, or vary wildly in composition between orders. Researchers cannot validate novel hypotheses, develop reliable protocols, or publish credible findings based on compounds of uncertain identity and purity. The 51% pass rate at Peptide Sciences means a researcher has roughly a coin-flip chance of receiving usable material.
Consumer-Protective Assessment: Proceed With Extreme Caution
Tutela Medical's assessment is unambiguous: Peptide Sciences' retatrutide does not meet acceptable standards for research-grade peptides. The 51% pass rate, identity failures indicating absent retatrutide, overfilling issues, and erratic batch quality across multiple testing periods constitute serious red flags. While the vendor's 41 independent tests provide transparency and Peptide Sciences' better performance on other peptides suggests some operational competency, the retatrutide line appears to suffer from chronic quality control failures. Researchers considering this source should demand current Finnrick Analytics reports for specific batch numbers, cross-reference against independent testing, and seriously consider alternative suppliers until Peptide Sciences demonstrates sustained improvements. The fact that only 51% of tests pass means researchers have nearly a 50% risk of receiving substandard or inert material—an unacceptable gamble for serious research. Potential buyers should also note that any side effects observed in Eli Lilly's clinical trials—including gastrointestinal effects (nausea, vomiting ~25%–30%), paresthesia, and elevated heart rate—would only manifest in compounds that actually contain the advertised retatrutide, further emphasizing the importance of quality assurance.
Compare Other GLP-3R Triple-Agonist Vendors
This review is part of our ongoing evaluation of research-grade retatrutide (GLP-3R) vendors. For a complete picture, see how other suppliers compare:
- Sourced Peptides vendor evaluation — ≥99% HPLC purity with batch-specific COA — among the more transparent vendors in this space
- The Amino Asylum Retatrutide Evaluation — Finnrick-rated 78% (#2 of 223 vendors) with mixed dosage results but consistent purity
- Swole Af Labs Vendor Assessment — UK-based vendor with no Finnrick-verified independent testing on record — transparency gaps noted
- Nationwide Peptides Vendor Analysis — Claims ≥99% purity with COA (HPLC/MS) and GMP synthesis — not yet Finnrick-verified
Each vendor review examines purity testing, dosage accuracy, pricing, and transparency — the factors that matter most for research-grade peptide procurement.
These statements have not been evaluated by the FDA. GLP-3R is a research peptide not intended for human consumption. Always consult a qualified healthcare provider before considering any research compounds.